Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.68 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42577 | 0.84 | IDO1 (0.65) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL5154843 | 0.82 | ADRA1A (0.70) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL1145887 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL479514 | 0.81 | TAAR1 (1.00) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL7524528 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL25308876 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL7060410 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL8867858 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL29491077 | 0.81 | TAAR1 (1.00) | ADRA1ATAAR1AOC3IDO1HTR2A | |
| SCHEMBL3149899 | 0.81 | ADRA1A (0.68) | ADRA1ATAAR1AOC3IDO1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2002-05-16 | — | — | US | claimed |
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CHEMRX ADVANCED TECHNOLOGIES, INC. | 2002-08-01 | — | — | US | disclosed |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001040193-A1 | METHOD FOR THE SYNTHESIS OF PYRAZOLINES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CYP2F1, CYP2E1, CYP3A7 | ADRA1A 1755/4885TAAR1 2118/4885AOC3 878/4885 |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DNPEP, LNPEP, NPEPPS | ADRA1A 4454/4885TAAR1 1082/4885AOC3 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.